Biopharma | May 07, 2026
China poised to launch world’s first CAR-T therapy for gastric cancer
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
The initiative pairs consumer engagement with a public health message about prevention and early detection
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The summit will bring together 1,200+ delegates, 100+ international faculty from 25 countries
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
Subscribe To Our Newsletter & Stay Updated
